IP Library › Granted Patent US 7,790,905
Granted Patent B2
US 7,790,905 · App. 10/747,742 · Granted Sep 7, 2010

Pharmaceutical propylene glycol solvate compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,790,905
App. No.
10/747,742
Granted
Sep 7, 2010
Kind
B2
Abstract

The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.

Claims (29)

1. A propylene glycol solvate of a sodium salt of celecoxib having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol.

2. A propylene glycol solvate of celecoxib sodium trihydrate having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

3. A propylene glycol solvate of celecoxib selected from:

a) a propylene glycol solvate of celecoxib sodium trihydrate characterized by a thermogravimetric analysis of FIG. 18 or FIG. 20 , said propylene glycol solvate of celecoxib sodium trihydrate having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate; or

b) a propylene glycol solvate of a sodium salt of celecoxib characterized by a thermogravimetric analysis of FIG. 1 , said propylene glycol solvate of a sodium salt of celecoxib having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol.

4. The propylene glycol solvate of celecoxib according to claim 3 , wherein the form is a propylene glycol solvate of celecoxib sodium trihydrate characterized by a thermogravimetric analysis of FIG. 18 , said propylene glycol solvate of celecoxib sodium trihydrate having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

5. The propylene glycol solvate of celecoxib according to claim 3 , wherein the form is a propylene glycol solvate of celecoxib sodium trihydrate characterized by a thermogravimetric analysis of FIG. 20 , said propylene glycol solvate of celecoxib sodium trihydrate having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

6. The propylene glycol solvate of celecoxib according to claim 3 , wherein the form is a propylene glycol solvate of a sodium salt of celecoxib characterized by a thermogravimetric analysis of FIG. 1 , said propylene glycol solvate of a sodium salt of celecoxib having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol.

7. A propylene glycol solvate of celecoxib selected from:

a) a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of FIG. 19 or FIG. 21 , said propylene glycol solvate of celecoxib sodium trihydrate having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate; or

b) a propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern of FIG. 2A , 2 B, 2 C or 2 D, said propylene glycol solvate of a sodium salt of celecoxib having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol.

8. The propylene glycol solvate according to claim 7 , wherein said propylene glycol solvate is a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of FIG. 19 and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

9. The propylene glycol solvate according to claim 7 , wherein said propylene glycol solvate is a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of FIG. 21 and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

10. The propylene glycol solvate according to claim 7 , wherein said propylene glycol solvate is a propylene glycol solvate of a sodium salt of celecoxib, said propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern of FIG. 2A , 2 B, 2 C or 2 D and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol.

11. The propylene glycol solvate according to claim 7 , wherein said propylene glycol solvate is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of FIG. 2A .

12. The propylene glycol solvate according to claim 7 , wherein said propylene glycol solvate is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of FIG. 2B .

13. The propylene glycol solvate according to claim 7 , wherein said propylene glycol solvate is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of FIG. 2C .

14. The propylene glycol solvate according to claim 7 , wherein said propylene glycol solvate is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of FIG. 2D .

15. A pharmaceutical composition comprising an excipient and a form of a propylene glycol solvate of celecoxib selected from:

a) a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of FIG. 19 or FIG. 21 , said propylene glycol solvate of celecoxib sodium trihydrate having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate; or

b) a propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern of FIG. 2A , 2 B, 2 C or 2 D, said propylene glycol solvate of a sodium salt of celecoxib having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol.

16. The composition according to claim 15 , wherein said form is a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of FIG. 19 or FIG. 21 and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

17. The composition according to claim 15 , wherein said form is a propylene glycol solvate of a sodium salt of celecoxib, said propylene glycol solvate of a sodium salt of celecoxib characterized by a PXRD pattern of FIG. 2A , 2 B, 2 C or 2 D and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol.

18. The composition according to claim 17 , wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of FIG. 2A .

19. The composition according to claim 17 , wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of FIG. 2B .

20. The composition according to claim 17 , wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of FIG. 2C .

21. The composition according to claim 16 , wherein said form is a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of FIG. 19 and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

22. The composition according to claim 16 , wherein said form is a propylene glycol solvate of celecoxib sodium trihydrate characterized by the PXRD pattern of FIG. 21 and having a stoichiometric ratio of 1 celecoxib: 1 sodium: 1 propylene glycol: 3 hydrate.

23. The composition according to claim 17 , wherein said form is a propylene glycol solvate of a sodium salt of celecoxib and said composition is characterized by the PXRD pattern of FIG. 2D .

Assignments (3)
MERGER AND CHANGE OF NAME Recorded Jul 2, 2015
From: MCNEIL-PPC, INC.; JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 036049/0254 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2010
From: TRANSFORM PHARMACEUTICALS, INC.
To: MCNEIL-PPC, INC.
Reel/Frame 024707/0159 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2004
From: TAWA, MARK; ALMARSSON, ORN; REMENAR, JULIUS F.
To: TRANSFORM PHARMACEUTICALS, INC.
Reel/Frame 014801/0115 →